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Summary
 Background: Psoriasis is an inflammatory disease characterized by increased squamous cell proliferation and 
impaired differentiation. Vitamin D, Calcitriol, and its analogues are successfully used for psoria-
sis therapy. However, it is unknown why some psoriasis patients are resistant to Vitamin D therapy. 
Vitamin D mediates its activity by a nuclear receptor. It is suggested that polymorphisms and hap-
lotypes in the VDR gene may explain the differences in response to vitamin D therapy.
 Material/Methods: In this study, 102 psoriasis patients and 102 healthy controls were studied for VDR gene polymor-
phisms. The Fok I, Bsm I, Apa I and Taq I polymorphisms were examined by PCR-RFLP, and 50 sub-
jects received vitamin D therapy to evaluate the association between VDR gene polymorphisms and 
response to vitamin D therapy. Existence of cutting site is shown by capital letters, and lack was 
shown by lower case. The haplotypes were analysed by CHAPLIN.
 Results: There was significant difference in allele frequency of T and genotype frequency of Tt between 
cases and controls (p values 0.038 and 0.04, respectively). The Aa and bb genotypes were signifi-
cantly higher in early onset than late onset psoriasis (p values 0.008 and 0.04, respectively). The 
genotypes Ff, ff and TT are significantly different between vitamin D3 therapy responders and 
non-responders (p values 0.04, 0.0001, 0.009, respectively). To the best of our knowledge, this is 
the first report showing importance of VDR gene haplotypes in psoriasis, the significance of the 
Wald and LR (Likelihood Ratio) statistics (p=0,0042) suggest that FfBbAatt is a disease-susceptibil-
ity haplotype.
 Conclusions: Haplotype analysis is a recent and commonly used method in genetic association studies. Our re-
sults reveal a previously unidentified susceptibility haplotype and indicate that certain haplotypes 
are important in the resistance to vitamin D3 therapy and the onset of psoriasis. The haplotypes 
can give valuable data where genotypes unable to do.
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Background
Psoriasis is a genetic disorder of the skin causing inflam-
matory disease, characterized by increased squamous cell 
proliferation and impaired differentiation. The CARD14 
gene was recently identified as the first gene directly linked 
to Psoriasis [1]. It is reported that more than 15 mutations 
and some polymorphisms are associated with the disease [2]. 
1,25(OH)2D3 is the endogenously produced, hormonally ac-
tive form of vitamin D3. In addition to the known effect of 
1,25(OH)2D3 on controlling calcium and bone metabolism, 
it inhibits proliferation and induces terminal differentiation 
of cultured human keratinocytes. It can also modulate the 
immune system in a variety of ways, enhancing immunosup-
pressive and anti-inflammatory pathways, which are its possi-
ble mechanisms of action in psoriasis lesions. Serum Vit D3 
levels can be low in psoriasis patients due to some extrinsic 
factors such as dietary or geographically low sun exposure. 
However, decreased levels of Vit D3 are not caused by vita-
min D deficiency [3–6]. 1,25(OH)2D3 elicits its action on 
target tissues through the vitamin D receptor (VDR). The 
receptor-hormone complex binds to hormone response el-
ements in regulatory regions of target genes, and modulates 
the gene transcription. However, it has been noted that cul-
tured fibroblasts and keratinocytes from some psoriatic pa-
tients have partial resistance to 1,25(OH)2D3-mediated an-
ti-proliferative activity [6,7]. Although therapeutic efficacy 
of 1a,25-dihydroxyvitamin D3 [1,25(OH)2D3] and its ana-
logues have been tested and proved to be effective for the 
treatment of psoriasis [8], clinical response to 1,25(OH)2D3 
treatment is variable in patients [9]. Experiments examin-
ing the anti-proliferative effects of calcitriol demonstrated 
that about 25% of psoriatic patients possessed dermal fibro-
blasts that exhibited partial resistance to calcitriol [7]. The 
gene encoding the VDR is known to contain a number of 
polymorphisms. A polymorphic start codon in the 5’ end of 
the gene is identified by the restriction enzyme FokI. In the 
3’ end of the gene, there are 3 polymorphisms generating 
BsmI, ApaI and TaqI restriction sites [10]. Molecular studies 
have shown that certain VDR polymorphisms could be asso-
ciated with bone mineral density, hyperparathyroidism, os-
teomalacia, insulin-dependent diabetes mellitus, osteoar-
thritis, and some malignancies such as breast and prostate 
carcinoma [10–14]. However, a number of negative and pos-
itive associations in different populations have been report-
ed. Genetic polymorphism of the VDR gene may influence 
1,25(OH)2D3-mediated normal physiologic response of kera-
tinocytes and can explain the variable responsiveness. In this 
study, we aimed to compare the allele and genotype frequen-
cies of VDR genotypes and haplotypes in psoriasis patients 
and healthy controls, and to determine the association be-
tween VDR polymorphism and response to vitamin D therapy.
Material and Methods
Patients
A total of 102 psoriasis patients (47 women and 55 men) 
and 102 controls (50 women and 52 men) were enrolled in 
this study. Psoriasis patients were diagnosed clinically and/or 
histopathologically. All the patients were clinically evaluat-
ed concerning their family history of psoriasis, nail involve-
ment, psoriatic arthralgia, and psoriasis area and severity in-
dex. Following a 2-week wash-out period during which no 
systemic or topical treatments were used, 50 patients were 
prescribed calcipotriol ointment and/or scalp solution and 
asked to apply the medication over the plaques twice daily 
for 6 weeks. The clinical response was assessed by psoriasis 
area and severity index (PASI). Patients were then grouped 
into 2 categories: non-responders (defined as improvement 
less than 50%) and responders (defined as improvement 
more than 50%) [15].
The protocol for this study was approved by the ethics com-
mittee of the Pamukkale University, Medical Faculty. Written 
informed consent was obtained from all volunteers.
VDR genotype analysis
The genotype for 4 SNPs of the VDR gene was determined 
by the digestion pattern of the amplified DNA fragments 
using the restriction enzymes Apa I, Bsm I, Fok I and Taq I. 
Blood samples were collected into K3EDTA-tubes and stored 
at –20°C. DNA was extracted from whole blood by a salting 
out procedure [16]. Genomic DNA was amplified by PCR 
using specific primers as previously described: for Apa I 
and Taq I primer-1, 5’-CAGAGCATGGACAGGGAGCAA-3’; 
primer-2, 5’-GCAACTCCTCATGGCTGAGGTCTC-3’ [17]; 
for Bsm I primer-3, 5’-CAACCAAGACTACAAGTACCGC 
GTCAGTGA-3’; primer-4, 5’-AACCAGCGGGAAGAGGTC 
AAGGG-3’ [18]; for Fok I primer-5, 5’-AGCTGGCCCTGGC 
ACTGACTCTGCTCT-3’; primer-6, 5’-ATGGAAACACCTTG 
CTTCTTCTCCCTC-3’ [19]. PCR was performed in a vol-
ume of 50 µl with 100 ng sample DNA, 200 µM dNTPs, 10 
pmol of each primer, 1.5 mM MgCl2, 1XPCR buffer and 1 
U Taq DNA polymerase (MBI Fermentas, Lithuania). PCR 
products were amplified in a programmable thermal cycler 
(Hybaid-PCRSprint, Middlesex, UK). The PCR conditions 
were 5 min at 94°C for initial denaturation, 30 sec at 94°C, 
30 sec at 60°C for Apa I, Taq I, Fok I, 65°C for Bsm I, 30 sec 
at 72°C, 30 cycles, followed by 5 min at 72°C for final ex-
tension. Specific PCR products were obtained 740 bp, 265 
bp and 825 bp for Apa I and Taq I, Fok I and Bsm I, respec-
tively. PCR products were digested with the restriction en-
zymes Apa I, Taq I, Bsm I (Mva1269I) and Fok I (BseGI) (MBI 
Fermentas, Lithuania) according to the manufacturer’s in-
structions, and electrophoresed on 1.4% or 1.7% agarose 
gels (Prona, Spain). For both BsmI and FokI, Apa I, and Taq 
I genotypes were defined by capital letters in the absence of 
the restriction site (A, B, F, T, respectively) and small letters 
where the restriction site was present (a, b, f, t, respectively).
Haplotype and statistical analysis
Allele frequencies were calculated from genotype frequen-
cies based upon Hardy-Weinberg equilibrium;
p, q: allele frequency, p2, q2, 2pq: genotype frequency.
p+q=1
(p2)+(2pq)+(q2)=1.
Haplotype analysis was done by CHAPLIN1.2 [20]. 
Differences in the VDR allele and genotype frequency 
were compared between psoriasis patients and controls by 
significance test between percentages. One-way analysis of 
variance was used to compare clinical parameters with gen-
otypes. The P value less than 0.05 was regarded as statisti-
cally significant, and analysis was carried out by SPSS9.0.
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results
Regardless of their clinical type, 102 random, unrelated 
Caucasian Turkish psoriasis patients (47 women, 55 men) 
aged 10 to 73 years (mean 44.36±16.35) and 102 unrelated, 
healthy Caucasian Turkish controls (50 women, 52 men) 
aged 15 to 75 years (mean 40.83±16.88) were included. No 
significance was found between mean age of female and 
male psoriasis patients. Of the 102 patients, 69 (67.6%) were 
plaque, 16 (15.7%) were plaque plus guttate, 10 (9.8%) were 
guttate, 5 (4.9%) were palmoplantar, and 2 (2%) were pus-
tular palmoplantar type of psoriasis (Table 1).
Patients were grouped according to their age of onset as 
Type I (early onset, <40 years old) and Type II (late on-
set, >40years old) psoriasis. Type I psoriasis was 63.7% 
and Type II psoriasis was 36.3% of all patients. Mean age 
at onset of all patient groups was 32.33±16.76, in the ear-
ly group 20.39±11.14 for women, 24.94±10.87 for men; in 
late group 47.47±6.45 for women, and 53.11±8.80 for men. 
There was no statistical significance between mean age of 
onset in female and male psoriasis patients. Nail involve-
ment and arthralgia were present in 32.4% and 38.2% of 
patients, respectively.
In total, 50 patients received calcipotriol therapy and 1 pa-
tient was excluded because of irritation and discarded from 
analysis. Of the 49 patients, 31 (63.3%) had improvement 
less than 50% and were grouped as non-responders, and 
18 (36.7%) patients had more than 50% response. We did 
not find any significance between response to calcipotriol 
therapy and sex, early and late onset of the disease, clini-
cal type, or family history (p>0.05).
Allele frequency of T and genotype frequency of Tt was sig-
nificantly higher in patients than controls (p values 0.038 
and 0.04, respectively) (Table 2). The Aa and bb geno-
types were significantly higher in early onset than late on-
set psoriasis (p values 0.008 and 0.04, respectively). The 
genotype Ff was significantly higher in non-responders, 
while ff and TT were significantly lower in non-respond-
ers to the vitamin D3 therapy (p values 0.04, 0.0001, 0.009, 
respectively).
This is the first report of importance a VDR gene haplo-
type in psoriasis (the significance of the Wald and LR sta-
tistics p=0.0042), suggesting that FfBbAatt is a disease-sus-
ceptibility haplotype.
discussion
The data related to VDR polymorphisms and psoriasis is 
very limited in the literature when compared with other sit-
uations such as bone mineral density, diabetes and cancers.
Lee et al. in 2012 [21] conducted a remarkable meta-analy-
sis and reported that overall association has not been found, 
while A allele, FF and ff genotypes are ethnically important 
in Turkish populations and B allele only in Asians. However, 
Zeul-Fakkar et al in 2010 [22] reported no association with 
Apa I and Taq I polymorphisms in Egyptian patients.
Dayangac et al. in 2007 [23] studied 51 Turkish psoriasis 
patients and reported that T allele and TT genotype was 
higher in patients, and also higher in non-responders of vi-
tamin D3 therapy, in contrast to the study of Halsall et al. 
in 2005 [24], who reported that T allele, TT and AA gen-
otypes are associated with response to vitamin D3 in white 
Caucasian patients. However, it was reported by Giomi et 
al. in 2005 [25] and Holick et al. in 1996 [26] Bb and bb 
genotypes are associated with response to vitamin D3 re-
spectively. Park et al. in 1999 [27] found AA and Aa geno-
types significantly higher in psoriasis patients, especially in 
the early onset group, and found no significance for BsmI 
and TaqI polymorphisms. Mee et al. in 1998 [9] found the 
Aa genotype has been associated with early onset of psori-
asis. Lee et al. in 2002 [28] and Kontula et al. in 1997 [29] 
reported there was no correlation between Bsm I and Apa 
I polymorphisms and clinical response.
Kaya et al. in 2002 [30] also studied 53 Turkish psoriasis 
vulgaris patients and reported the Aa and aa genotypes as 
a high risk for psoriasis vulgaris in the Turkish population. 
Neither this study nor Dayangac et al. in 2007 [23] have 
found association with Apa I polymorphism. Okiata et al. 
in 2002 [31] reported that AA genotype was higher in pus-
tulosis palmaris et plantaris than in psoriasis vulgaris than 
in psoriasis pustulosa; however, there was no correlation be-
tween PASI score and age at onset.
In terms of haplotype, Rucevic et al. in 2012 [32] did not find 
any association with the 3’ region of the VDR gene. Halsall 
et al. in 2005 [24] found a powerful correlation with com-
bined genotypes AAFF, AATT and FFTT. The haplotypes 
are tags which are sum of the marker polymorphisms in a 
gene. Individually, SNPs and genotypes may not have sig-
nificance and association, but together as haplotype they 
can. The haplotype we found may indicate that a special fi-
nal vitamin D receptor protein is made susceptible to pso-
riasis by changing RNA splicing, processing and editing, or 
by changing receptor protein folding or changing by affinity 
and binding specifically to DNA response elements or other 
nuclear receptors, which function as hetero/homodimers or 
functional structures of receptors. The VDR is a regulatory 
protein, and its final haplotype may disrupt the regulatory 
function and may complement the other disturbing factors. 
This may be confirmed by studying interaction and activity 
characteristics of VDR protein in these subjects. In addition, 
transcriptome results, which were provided by Jordan et al. 
[2], can give some clues about the starting point.
Morrison et al. in 1992 [18] reported that the b allele tends 
to decrease VDR mRNA expression. Chen et al. in 1996 
[33] reported that VDR expression has been induced in 
psoriatic lesion of patients who received vitamin D, indict-
ing that vitamin D3 induced the expression of VDR mRNA 
in responders but not in non-responders. They suggested 
that the medication played a role in regulation of epidermal 
keratinocytes and fibroblast proliferation, or in some oth-
er way affected lymphocyte migration and proliferation in 
psoriatic lesions. It is remarkable that Apa I polymorphisms 
A, and in some cases T (Taq I), are often reported in asso-
ciation with psoriasis. The mechanism of vitamin D3 thera-
py and the cause of the resistance in some patients still re-
main unclear. The Apa I polymorphisms are in the intronic 
site of the gene, and its importance may be explained by in-
trons playing a role in control of expression through RNA 
editing and alternative splicing.
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16 F 42 + 1 0 100 Plaque + + – 41 01 +
23 F 55 + 2 0 100 Plaque – – – 48 07 –
37 M 50 + 1 0 100 Plaque – – – 48 02 –
49 M 33 + 1 0 100 Plaque – – – 25 08 –
20 M 35 + 1 0 100 G + P – – – 29 06 –
4 F 20 + 1 0 86 Plaque – – + 15 05 –
25 M 19 + 1 0 50 Plaque – – – 17 02 –
34 M 19 + 1 0 60 Plaque + + – 05 14 +
22 M 61 + 4 1 83 G + P – – + 51 10 –
11 F 37 + 2 1 65 Plaque – – – 27 10 –
42 M 71 + 2 1 63 Plaque + + – 61 10 –
13 M 25 + 4 1 78 Guttate – – – 19 06 –
8 F 56 + 3 1 57 Plaque – – – 36 20 +
36 F 21 + 2 1 50 Guttate – – + 16 05 +
2 F 34 + 3 1 53 Palmoplantar – – – 34 00 +
47 M 24 + 4 2 56 Plaque – – – 12 12 –
28 M 44 + 4 2 50 Plaque – – – 43 01 –
5 F 61 +  10 3 67 G + P + + – 46 15 –
3 F 53 – 2 1 25 Plaque + + – 46 07 –
24 F 41 – 2 1 25 Plaque + + – 36 05 –
31 F 55 – 1 1 14 Plaque + + – 54 01 –
30 M 72 – 2 2 17 Plaque – + + 66 06 –
15 F 38 – 1 2 –23 Plaque + + + 28 10 –
17 F 65 – 2 2 00 Plaque – – + 40 25 –
21 M 70 – 2 2 27 Plaque + + – 40 30 +
33 F 42 – 3 2 43 Plaque – – – 30 12 +
10 F 48 – 1 2 –14 Palmoplantar + + + 43 05 –
45 M 50 – 2 2 17 Plaque – – – 40 10 –
14 F 44 – 2 2 17 Palmoplantar – – – 43 01 –
46 M 50 – 2 2 17 Palmoplantar – – – 40 10 –
19 F 38 – 3 2 29 Plaque + + – 06 32 +
12 F 10 – 2 2 –35 Plaque – – – 05 05 –
27 F 33 – 4 3 32 G + P – – + 18 15 –
38 M 47 – 2 3 –17 Plaque – – – 27 20 –
1 M 50 – 4 4 00 Plaque – – – 40 10 –
40 F 45 – 7 4 45 Guttate – – – 44 01 –
Table 1. Clinical summary of the patients.
Clinical Research Med Sci Monit, 2012; 18(11): CR661-666
CR664
In conclusion, the findings indicate that VDR polymor-
phisms may affect response to vitamin D3 therapy and on-
set of psoriasis.
conclusions
The number of markers used for genetic association studies 
are increasing rapidly. After the SNPs era, the copy number 
variations became very popular and useful in these days, as 
well junk DNA imminent will become. Genotype analysis 
has been used for a long time. However, haplotype analysis 
has recently become important due to the newly developed 
bioinformatics packets. Every haplotype can be used for 
creation of haploblocks and tagging. In the view of VDR 
and psoriasis, only 2 haplotypes were found, including this 
study. We believe that every association found makes great 
contribution to our understanding of the resistance to vi-
tamin D3 therapy in psoriasis. These data can be clarified 
by the structure-function and binding characteristics stud-
ies of the related VDR protein.
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